Zymeworks Inc.

NASDAQ:ZYME

Biotechnology

Healthcare
$26.86 -1.64%

-$0.38 today

Market cap
$1.87B
Beta
1.14
P/E (TTM)
-16.6
EPS (TTM)
-$1.37
52W Low $11.51High $29.75

Volume 0.99M

Average 0.71M

Returns on capital

Zymeworks Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-30.2%

avg -65.4%

ROIC

-30.1%

avg -37.0%

ROA

-23.4%

avg -29.1%

Analysis

ROA is currently the strongest return metric at -23.4% versus its period average of -29.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Kenneth H. Galbraith

Chairman of the Board, Chief Executive Officer & PresidentUSD 1.71M64——

Paul Moore

Chief Scientific OfficerUSD 998.37K59——

Sabeen Mekan

Senior VP & Chief Medical Officer—460<0.01%

Stuart Knight

Executive VP & Chief Information Officer————

Bijal Desai

Senior Vice President of Finance————

Shrinal Inamdar

Vice President of Investor Relations————

Lindsey Foulkes

Senior Vice President of Corporate Development & Strategy————

Mark Hollywood

Executive VP & Chief Operating Officer—57133.85K0.18%

Paul R. Schneider

Executive VP & General Counsel—550<0.01%

Laura O'Connor

Senior VP & Chief Human Resources Officer————

Scott Platshon

Executive VP & Chief Business Officer—350<0.01%

Diana Papove

Vice President of Corporate Communications————

Kristin Stafford

Executive VP & CFO—4450.00K0.07%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 6, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

11

$5.03M

Net Transaction Value

−$5.03M

Net selling

Most Active

Galbraith Kenneth

4 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 9, 26

Schayowitz Adam

Direct

Sell$357.6K
Jan 12, 26

Hollywood Mark

Direct

Sell$138.8K
Jan 12, 26

Smith Jeffrey T L

Direct

Sell$211.1K
Jan 12, 26

Moore Paul Andrew

Direct

Sell$216.8K
Jan 12, 26

Galbraith Kenneth

Direct

Sell$689.8K
Jan 5, 26

Moore Paul Andrew

Direct

Sell$271.6K
Jan 5, 26

Moore Paul Andrew

Direct

Sell$233.1K
Jan 5, 26

Galbraith Kenneth

Direct

Sell$795.2K
Jan 5, 26

Galbraith Kenneth

Direct

Sell$568.6K
Jan 5, 26

Smith Jeffrey T L

Direct

Sell$264.5K

1–10 of 11

Summary

Insiders reported 0 buys worth $0.00 and 11 sells worth $5.03M over the last 12 months. That adds up to net selling of $5.03M. Galbraith Kenneth was the most active insider with 4 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A3 analysts
RevenueN/AN/A-36.4%
+36.2% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Recent growth has been strongest in Revenue at -36.4% over three years. Forward estimates point to Revenue at +36.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Zymeworks Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ZYME's management, answered from reported figures.

Who manages ZYME?

Zymeworks Inc. (ZYME) lists 13 active executives. The top listed executive is Sabeen Mekan, Senior VP & Chief Medical Officer.

Are ZYME insiders buying or selling?

Recent insider activity shows net buying of $102.50M.